Lipid microparticles for mucosal immunization against hepatitis B.
Parenteral administration of vaccines often does not lead to optimal or long lasting protection against disease causing organisms particularly those that are inhaled, ingested or sexually transmitted. For optimal mucosal protection induction of immune response via mucosal routes is therefore highly desirable. Double emulsion-solvent evaporation (w/o/w) method best suited for water-soluble bioactives was selected for the preparation of hepatitis B surface antigen (HBsAg) loaded lipid microparticles. Intranasal route was considered for mucosal administration and hence to prepare the delivery system biocompatible and least irritable, soyalecithin (phospholipid) was taken instead of polymer because phosphatidylcholine is the major component of endogenous lung surfactant. The studies performed in present work included antigen characterization, development of lipid microparticles, stability studies of the prepared lipid microparticle formulations, percent mucoadhesion, ex vivo cellular uptake studies and in vivo studies. The general order obtained from in vivo studies for mucosal immune response (IgA) followed the sequence: LMST-HBsAg (IN)>LM-HBsAg (IN)>alum-HBsAg (IN)>LMST-HBsAg (IM)>alum-HBsAg (IM)>or=LM-HBsAg (IM)>plain HBsAg (IN)>plain HBsAg (IM).
Saraf
Surbhi
S
Department of Pharmaceutical Sciences, Dr. H. S. Gour University, Sagar, Madhya Pradesh 470003, India.
Mishra
Dinesh
D
Asthana
Abhay
A
Jain
Renu
R
Singh
Surinder
S
Jain
N K
NK
D000281:Administration, Intranasal; D000818:Animals; D004355:Drug Stability; D004655:Emulsions; D006509:Hepatitis B / Q000517:prevention & control*; D006514:Hepatitis B Surface Antigens / Q000008:administration & dosage* / Q000276:immunology; D018928:Immunity, Mucosal; D007114:Immunization; D008264:Macrophages / Q000378:metabolism; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley
D004655:Emulsions; D006514:Hepatitis B Surface Antigens